DAVID J. GURY was elected President, Chairman of the Board and
Chief Executive Officer of Nabi Biopharmaceuticals in April 1992.
In May 1984, Mr. Gury joined Nabi as President and Chief
Operating Officer. Prior to joining Nabi Biopharmaceuticals, Mr.
Gury spent his career with Abbott Laboratories in various
administrative and executive positions and with Alpha
Therapeutics Corporation, a spinout from Abbott. Mr. Gury
completed his AB in Economics at Kenyon College, Gambier, Ohio,
in 1960 and received his MBA at the University of Chicago in
1962, specializing in Accounting and Finance. His undergraduate
junior year was spent at the University of Madrid, Spain. He was
a Research Fellow at the University of Chicago and an intern with
Arthur Andersen & Co. In addition to his duties at Nabi
Biopharmaceuticals, Mr. Gury is a member of the Florida Emerging
Technology Commission, Chairman of the Florida Research
Consortium and past Chairman and a member of BioFlorida. Profile
TWST: Would you give us an update on the company? What has gone on over
the past year or so that investors should focus on?
Mr. Gury: In 2001, we had four major goals for the company. The